Abstract
Molecular imaging represents an extremely important advancement in patient care and numerous agents have been developed and are being studied. Hundreds of molecular imaging agents currently exist for use in multiple modalities such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, optical imaging, general nuclear medicine and positron emission tomography (PET). In PET, only a very small percentage of these agents are being used clinically in humans and more show promise for clinical use in the short-term future. The purpose of this paper is to present a brief overview of PET agents other than 18F-fluordeoxyglucose (FDG) that are either currently in clinical use in humans or in the authors opinion are felt to show great promise for clinical use in the near future.
Keywords: Molecular imaging, molecular imaging agents, positron emission tomography, PET, PET/CT
Current Pharmaceutical Biotechnology
Title: Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Volume: 11 Issue: 6
Author(s): Lance T. Hall, Aaron F. Struck and Scott B. Perlman
Affiliation:
Keywords: Molecular imaging, molecular imaging agents, positron emission tomography, PET, PET/CT
Abstract: Molecular imaging represents an extremely important advancement in patient care and numerous agents have been developed and are being studied. Hundreds of molecular imaging agents currently exist for use in multiple modalities such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, optical imaging, general nuclear medicine and positron emission tomography (PET). In PET, only a very small percentage of these agents are being used clinically in humans and more show promise for clinical use in the short-term future. The purpose of this paper is to present a brief overview of PET agents other than 18F-fluordeoxyglucose (FDG) that are either currently in clinical use in humans or in the authors opinion are felt to show great promise for clinical use in the near future.
Export Options
About this article
Cite this article as:
T. Hall Lance, F. Struck Aaron and B. Perlman Scott, Clinical Molecular Imaging with PET Agents Other than 18F-FDG, Current Pharmaceutical Biotechnology 2010; 11 (6) . https://dx.doi.org/10.2174/138920110792246537
DOI https://dx.doi.org/10.2174/138920110792246537 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Machine Learning and Artificial Intelligence for Medical Data Analysis and Human Information Analysis in Healthcare
The intersection of machine learning (ML) and artificial intelligence (AI) with the pharmaceutical industry is revolutionizing traditional paradigms in drug discovery and development. These technologies have introduced innovative approaches to analyzing complex datasets and predicting chemical properties, leading to more efficient identification and optimization of drug candidates. By employing sophisticated ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Dynamics of Protein Kinase-Inhibitor Complexes: A Valid Structural Information
Current Pharmaceutical Design Design and Efficient Synthesis of Novel 4,5-Dimethylthiazole-Hydrazone Derivatives and their Anticancer Activity
Letters in Drug Design & Discovery Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design Current Inhibitors of Checkpoint Kinase 2
Current Medicinal Chemistry Rotundic Acid Regulates the Effects of Let-7f-5p on Caco2 Cell Proliferation
Anti-Cancer Agents in Medicinal Chemistry Pathophysiological Functions of the lncRNA TUG1
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Medicinal Chemistry A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Review on the Artificial Intelligence-based Nanorobotics Targeted Drug Delivery System for Brain-specific Targeting
Current Pharmaceutical Design Applications of Molecular Imaging in Cancer Gene Therapy
Current Gene Therapy Bioconjugation of Ionophore Antibiotics: A Way to Obtain Hybrids with Potent Biological Activity
Mini-Reviews in Organic Chemistry Hypoxia-Inducible Factor-1 as Regulator of Angiogenesis in Rheumatoid Arthritis - Therapeutic Implications
Current Medicinal Chemistry Oncolytic Viruses: The Best is Yet to Come
Current Cancer Drug Targets Blocking Ca2+ Entry: A Way to Control Cell Proliferation
Current Medicinal Chemistry Hydrogel-clay Nanocomposites as Carriers for Controlled Release
Current Medicinal Chemistry Decreased Cerebral Perfusion in Chronic Migraine: A Voxel-based Cerebral Blood Flow Analysis Using 3D Pseudo-continuous Arterial Spin Labeling
Current Medical Imaging DNA Demethylation: Where Genetics Meets Epigenetics
Current Pharmaceutical Design Molecular Mechanism of Anti-tumor Effect by Triptolide in Hematological Malignancies
Current Signal Transduction Therapy A Network Biology Approach for Assessing the Role of Pathologic Adipose Tissues in Insulin Resistance Using Meta-analysis of Microarray Datasets
Current Genomics